Ethocle Reports has published its latest Market Research Report on EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2025. Develop business strategies by understanding the trends shaping and driving the global UC market. Browse market data tables and figures.

1. EpiCast Report: Ulcerative Colitis - EpidemiologyForecastto 2025
Ethocle Reportshaspublished its latest MarketResearch Reporton EpiCast Report: Ulcerative Colitis -
EpidemiologyForecastto 2025. Develop businessstrategiesby understanding the trendsshaping and
driving the globalUC market. Browsemarketdata tablesand figures.
PublishedOn:01-Jan-2017 | Pages:101
Summary
Ulcerative colitis(UC) isaninflammatorybowel disease(IBD) characterizedbylong-lastinginflammation
and ulcers(sores) inthe liningof the digestive tract.InUC, because of an abnormal response of the
body’simmune system,the liningof the colonbecomes inflamedanddevelopstinyopensores,or
ulcers,thatproduce pus andmucous.Thiscauses abdominal discomfortandfrequentemptyingof the
colon.There isno cure forUC exceptsurgical removal of the colon,butmedicationscanhelpcurbthe
inflammatoryresponse andsymptoms.UCcommonlyaffectsteenagersandyoungadults,andcan result
inpoor developmentandgrowth;nonetheless,the disease canalsooccur inchildrenandolder
individuals.
In the 7MM, GlobalDataepidemiologistsforecastthatthe diagnosedincidentcasesof UC will increase
from86,509 casesin2015 to 95,864 cases in2025, at an annual growthrate (AGR) of 1.08%. The US will
have the highestnumberof diagnosedincidentcasesof UC overthe forecastperiod,while Spainwill
have the lowest.
In the 7MM, GlobalDataepidemiologistsforecastthatthe diagnosedprevalentcasesof UC will increase
from1,628,113 casesin 2015 to 1,711,603 casesin2025, at an AGR of 0.51%. The US will have the
highestnumberof diagnosedprevalentcasesof UCover the forecastperiod,while Spainwill have the
lowest.
To forecastthe diagnosedincidentanddiagnosedprevalentcasesof UC inthe 7MM, GlobalData
epidemiologistsusedcountry-specificstudiesandpeer-reviewedjournalsthatprovidedage- andsex-
specificdiagnosedincidenceand/ordiagnosedprevalence of UCin the respective markets.The forecast
methodologywasconsistentacrossthe 7MM to allow fora meaningful comparisonof the forecast
incidentandprevalentcasesof UCacross these markets.
Click here to find out more about this report?
Scope

2. - The Ulcerative Colitis(UC) EpiCastReportprovides anoverview of the riskfactorsandglobal trendsof
UC inthe sevenmajormarkets(7MM) (US, France,Germany,Italy,Spain,UK,and Japan).Itincludesa
10-year epidemiological forecastforthe diagnosedincidentcases,diagnosedprevalentcases,
undiagnosedprevalentcases,andtotal prevalentcasesof UCsegmentedbysex andage inthese seven
markets.The diagnosedincidentcasesare furthersegmentedbystage atdiagnosisandseveritygrading.
The diagnosedprevalentcasesare furthersegmentedbyseveritygrading.Additionally,autoimmune
comorbidities,colectomydue tofailure of medical management,andmortalitydue tocomplicationsof
UC amongthe diagnosedprevalentcasesof UC are also includedinthisanalysis.Furthermore,the
reportincludesdiagnosedincidentcasesanddiagnosedprevalentcasesof indeterminatecolitis(IC) for
bothsexesandall agesin the 7MM.
- The UC epidemiologyreportiswrittenanddevelopedbyMasters- andPhD-levelepidemiologists.
- The EpiCastReportis in-depth,highquality,transparentandmarket-driven,providingexpertanalysis
of disease trendsinthe 7MM.
Get Free Sample Report
Click here for Discounts
Reasons to buy
The UC EpiCastreportwill allowyouto -
- Develop businessstrategiesbyunderstandingthe trendsshapinganddrivingthe global UCmarket.
- Quantifypatientpopulationsinthe global UCmarketto improve productdesign,pricing,andlaunch
plans.
- Organize salesandmarketingeffortsbyidentifyingthe age groupsandsex thatpresentthe best
opportunitiesforUC therapeuticsineachof the marketscovered.
- Identifythe percentage of diagnosedincidentcasesof UC by stage at diagnosisandseveritygrading.
Table of Contents
1.1 Listof Tables7
1.2 Listof Figures9
2 Epidemiology11

3. 2.1 Disease Background11
2.2 RiskFactors and Comorbidities12
2.3 Global Trends13
2.3.1 Incidence 14
2.3.2 Prevalence 17
2.4 ForecastMethodology20
2.4.1 SourcesUsed20
2.4.2 ForecastAssumptionsandMethods31
2.4.3 SourcesNotUsed 49
2.5 Epidemiological ForecastforUC (2015-2025) 50
2.5.1 DiagnosedIncidentCasesof UC50
2.5.2 DiagnosedPrevalentCasesof UC58
2.5.3 UndiagnosedPrevalentCasesof UC69
2.5.4 Total PrevalentCasesof UC76
2.5.5 DiagnosedIncidentCasesof IC83
2.5.6 DiagnosedPrevalentCasesof IC85
2.6 Discussion86
2.6.1 Epidemiological ForecastInsight86
2.6.2 Limitationsof the Analysis87
2.6.3 Strengthsof the Analysis88
3 Appendix90
3.1 Bibliography90
3.2 PhysiciansandSpecialists IncludedinthisStudy95
3.3 Aboutthe Authors97
3.3.1 Epidemiologists97

4. 3.3.2 Reviewers97
3.3.3 Global Directorof TherapyAnalysisandEpidemiology98
3.4 AboutGlobalData99
3.5 AboutEpiCast99
3.6 Disclaimer100 1.1 Listof Tables
Table 1: RiskFactorsand ComorbiditiesforUCand IBD 12
Table 2: Incidence of UCin the 5EU 16
Table 3: Prevalenceof UC inItaly,Spain,andthe UK 19
Table 4: 7MM, SourcesUsedto Forecastthe DiagnosedIncidentCasesof UC 21
Table 5: 7MM, SourcesUsedto Forecastthe DiagnosedPrevalentCasesof UC22
Table 6: 7MM, SourcesUsedto ForecastUndiagnosedPrevalentCasesof UC23
Table 7: 7MM, SourcesUsedto Forecastthe Total PrevalentCasesof UC 24
Table 8: 7MM, SourcesUsedto Forecastthe Diagnosed IncidentCasesof UC byStage at Diagnosis25
Table 9: 7MM, Sourcesof Epidemiological DataUsedto Forecastthe DiagnosedIncident/Prevalent
Casesof UC by Severity26
Table 10: 7MM, Sourcesof Epidemiological DatausedtoForecastMortalityDue to CRC andTMC Among
the DiagnosedPrevalentCasesof UC27
Table 11: 7MM, SourcesUsedto ForecastAutoimmune ComorbiditiesAmongthe DiagnosedPrevalent
Casesof UC 28
Table 12: 7MM, SourcesUsedto ForecastUC CasesRequiringColectomyAmongthe Diagnosed
PrevalentCasesof UCDue to Failure of Medical Management29
Table 13: 7MM, SourcesUsedto Forecastthe DiagnosedIncidentCasesof IC30
Table 14: 7MM, SourcesUsedto Forecastthe DiagnosedPrevalentCasesof IC31
Table 15: 7MM, SourcesNotUsedin Epidemiological Analysisof UC 49
Table 16: 7MM, DiagnosedIncidentCasesof UC,Both Sexes,All Ages,N,SelectedYears2015-2025 50
Table 17: 7MM, Age-SpecificDiagnosedIncidentCasesof UC,Both Sexes,N (Row %),2015 52
Table 18: 7MM, Sex-SpecificDiagnosedIncidentCasesof UC,All Ages,N (Row %),2015 54

5. Table 19: 7MM, DiagnosedPrevalentCasesof UC,Both Sexes,All Ages,N,SelectedYears,2015-2025 59
Table 20: 7MM, Age-SpecificDiagnosedPrevalentCasesof UC,Both Sexes,N (Row %),2015 61
Table 21: 7MM, Sex-SpecificDiagnosedPrevalentCasesof UC,All Ages,N (Row %),2015 63
Table 22: 7MM, UndiagnosedPrevalentCasesof UC,Both Sexes,All Ages,N,SelectYears,2015-2025 70
Table 23: 7MM, Age-SpecificUndiagnosedPrevalentCasesof UC,Both Sexes,N (Row %),2015 72
Table 24: 7MM, Sex-SpecificUndiagnosedPrevalentCasesof UC,All Ages,N (Row %),2015 74
Table 25: 7MM, Total PrevalentCasesof UC,Both Sexes,All Ages,N,SelectedYears,2015-2025 77
Table 26: 7MM, Age-SpecificTotal Prevalent Casesof UC,Both Sexes,N (Row %),2015 79
Table 27: 7MM, Sex-SpecificTotal PrevalentCasesof UC,All Ages,N (Row %),2015 81
Table 28: 7MM, DiagnosedIncidentCasesof IC,BothSexes,All Ages,N,SelectedYears,2015-2025 84
Table 29: 7MM, Diagnosed PrevalentCasesof IC,BothSexes,All Ages,N,SelectedYears,2015-2025 85
1.2 Listof Figures
Figure 1: 7MM, DiagnosedIncidentCasesof UC,Both Sexes,All Ages,SelectedYears,2015-2025 51
Figure 2: 7MM, Age-SpecificDiagnosedIncidentCasesof UC,Both Sexes,All Ages,N,2015 53
Figure 3: 7MM, Sex-SpecificDiagnosedIncidentCasesof UC,All Ages,N,2015 55
Figure 4: 7MM, Age-StandardizedDiagnosedIncidence of UC(Casesper100,000 Population),All Ages,
Both Sexes,N,2015 56
Figure 5: 7MM, DiagnosedIncidentCasesof UCSegmentedbyStage at Diagnosis,BothSexes,All Ages,
N,2015 57
Figure 6: 7MM, DiagnosedIncidentCasesof UCSegmentedbySeverity,BothSexes,All ages,N,2015 58
Figure 7: 7MM, DiagnosedPrevalentCasesof UC,BothSexes,All Ages,SelectedYears,2015-2025 59
Figure 8: 7MM, Age-SpecificDiagnosedPrevalentCasesof UC,Both Sexes,N,2015 62
Figure 9: 7MM, Sex-SpecificDiagnosedPrevalentCasesof UC,All Ages,N,2015 64
Figure 10: 7MM, Age-StandardizedDiagnosedPrevalenceof UC,All Ages,BothSexes,%,2015 65
Figure 11: 7MM, DiagnosedPrevalentCasesof UCSegmentedbySeverity,BothCases,All Ages,N,2015
66

6. Figure 12: 7MM, MortalityDue to ComplicationsAmongthe DiagnosedPrevalentCasesof UC,Both
Sexes,All Ages, N,2015 67
Figure 13: 7MM, ColectomyDue toFailure of Medical ManagementAmongthe DiagnosedPrevalent
Casesof UC, BothSexes,All Ages,N,2015 68
Figure 14: 7MM. ComorbiditiesAmongthe DiagnosedPrevalentCasesof UC,Both Sexes,All Ages,N,
2015 69
Figure 15: 7MM, UndiagnosedPrevalentCasesof UC,BothSexes,All Ages,SelectedYears,N,2015-2025
71
Figure 16: 7MM, Age-SpecificUndiagnosedPrevalentCasesof UC,BothSexes,N,2015 73
Figure 17: 7MM, Sex-SpecificUndiagnosedPrevalentCasesof UC, All Ages,N,2015 75
Figure 18: 7MM, Age-StandardizedUndiagnosedPrevalence of UC,All Ages,BothSexes,%,2015 76
Figure 19: 7MM, Total PrevalentCasesof UC,BothSexes,All Ages,SelectedYears,N,2015-2025 77
Figure 20: 7MM, Age-SpecificTotal PrevalentCasesof UC,BothSexes,N,2015 80
Figure 21: 7MM, Sex-SpecificTotal PrevalentCasesof UC,All Ages,N,2015 82
Figure 22: 7MM, Age-StandardizedTotal Prevalence of UC,All Ages,BothSexes,%,2015 83
Figure 23: 7MM, DiagnosedIncidentCasesof IC,BothSexes,AllAges,SelectedYears,N,2015-2025 84
Figure 24: 7MM, DiagnosedPrevalentCasesof IC,BothSexes,All Ages,SelectedYears,N,2015-2025 86